Orphan Technologies begins OT-58 phase 1/2 trial in classical homocystinuria

pharmanewsdaily- February 16, 2019 0

OT-58 clinical trial news : Swiss pharma company Orphan Technologies has dosed the first patients in a phase 1/2 trial, called CBS-HCY-01, of its modified ... Read More